市場調査レポート：世界の切除不能肝細胞がん治療市場（～2028年）：新規T細胞治療、化学治療

• 英文タイトル：Global Unresectable Hepatocellular Carcinoma Treatment Market Insights, Forecast to 2028

Global Unresectable Hepatocellular Carcinoma Treatment Market Insights, Forecast to 2028「世界の切除不能肝細胞がん治療市場（～2028年）：新規T細胞治療、化学治療」（市場規模、市場予測）調査レポートです。

• レポートコード：MRC2Q12-16859
• 出版社/出版日：QYResearch / 2022年12月
• レポート形態：英文、PDF、105ページ
• 納品方法：Eメール（納期：3営業日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、切除不能肝細胞がん治療のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。
切除不能肝細胞がん治療のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
切除不能肝細胞がん治療の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
切除不能肝細胞がん治療のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。

生産面において、本レポートは2017年から2022年までの切除不能肝細胞がん治療の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の切除不能肝細胞がん治療の売上および2028年までの予測に焦点を当てています。

切除不能肝細胞がん治療のグローバル主要企業には、Pfizer Inc.、Eli Lilly、Bayer AG、Merck & Co. Inc.、Bristol-Myers-Squibb Company、Celgene Corporation、Eisai Co. Ltd、F. Hoffmann-La Roche Ltd、Chugai Pharmaceutical Co. Ltd、Pharmaxis、BeiGene、Astrazeneca PLCなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

切除不能肝細胞がん治療市場は、タイプとアプリケーションによって区分されます。世界の切除不能肝細胞がん治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。

【タイプ別セグメント】
新規T細胞治療、化学治療

【アプリケーション別セグメント】
病院、クリニック、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 切除不能肝細胞がん治療製品概要
- タイプ別市場（新規T細胞治療、化学治療）
- アプリケーション別市場（病院、クリニック、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の切除不能肝細胞がん治療販売量予測2017-2028
- 世界の切除不能肝細胞がん治療売上予測2017-2028
- 切除不能肝細胞がん治療の地域別販売量
- 切除不能肝細胞がん治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別切除不能肝細胞がん治療販売量
- 主要メーカー別切除不能肝細胞がん治療売上
- 主要メーカー別切除不能肝細胞がん治療価格
- 競争状況の分析
- 企業M&A動向
・タイプ別市場規模（新規T細胞治療、化学治療）
- 切除不能肝細胞がん治療のタイプ別販売量
- 切除不能肝細胞がん治療のタイプ別売上
- 切除不能肝細胞がん治療のタイプ別価格
・アプリケーション別市場規模（病院、クリニック、その他）
- 切除不能肝細胞がん治療のアプリケーション別販売量
- 切除不能肝細胞がん治療のアプリケーション別売上
- 切除不能肝細胞がん治療のアプリケーション別価格
・北米市場
- 北米の切除不能肝細胞がん治療市場規模（タイプ別、アプリケーション別）
- 主要国別の切除不能肝細胞がん治療市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの切除不能肝細胞がん治療市場規模（タイプ別、アプリケーション別）
- 主要国別の切除不能肝細胞がん治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の切除不能肝細胞がん治療市場規模（タイプ別、アプリケーション別）
- 主要国別の切除不能肝細胞がん治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の切除不能肝細胞がん治療市場規模（タイプ別、アプリケーション別）
- 主要国別の切除不能肝細胞がん治療市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの切除不能肝細胞がん治療市場規模（タイプ別、アプリケーション別）
- 主要国別の切除不能肝細胞がん治療市場規模（トルコ、サウジアラビア）
・企業情報
Pfizer Inc.、Eli Lilly、Bayer AG、Merck & Co. Inc.、Bristol-Myers-Squibb Company、Celgene Corporation、Eisai Co. Ltd、F. Hoffmann-La Roche Ltd、Chugai Pharmaceutical Co. Ltd、Pharmaxis、BeiGene、Astrazeneca PLC
・産業チェーン及び販売チャネル分析
- 切除不能肝細胞がん治療の産業チェーン分析
- 切除不能肝細胞がん治療の原材料
- 切除不能肝細胞がん治療の生産プロセス
- 切除不能肝細胞がん治療の販売及びマーケティング
- 切除不能肝細胞がん治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 切除不能肝細胞がん治療の産業動向
- 切除不能肝細胞がん治療のマーケットドライバー
- 切除不能肝細胞がん治療の課題
- 切除不能肝細胞がん治療の阻害要因
・主な調査結果

Market Analysis and Insights: Global Unresectable Hepatocellular Carcinoma Treatment Market
The global Unresectable Hepatocellular Carcinoma Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Novel T Cell Therapy accounting for % of the Unresectable Hepatocellular Carcinoma Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Unresectable Hepatocellular Carcinoma Treatment market size is valued at US$ million in 2021, while the North America and Europe Unresectable Hepatocellular Carcinoma Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Unresectable Hepatocellular Carcinoma Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Unresectable Hepatocellular Carcinoma Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Unresectable Hepatocellular Carcinoma Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Unresectable Hepatocellular Carcinoma Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Unresectable Hepatocellular Carcinoma Treatment market.
Global Unresectable Hepatocellular Carcinoma Treatment Scope and Market Size
Unresectable Hepatocellular Carcinoma Treatment market is segmented by players, region (country), by Treatment Method and by Application. Players, stakeholders, and other participants in the global Unresectable Hepatocellular Carcinoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Treatment Method and by Application for the period 2017-2028.
Segment by Treatment Method
Novel T Cell Therapy
Chemotherapy
Segment by Application
Hospitals
Clinics
Others
By Company
Pfizer Inc.
Eli Lilly
Bayer AG
Merck & Co. Inc.
Bristol-Myers-Squibb Company
Celgene Corporation
Eisai Co. Ltd
F. Hoffmann-La Roche Ltd
Chugai Pharmaceutical Co. Ltd
Pharmaxis
BeiGene
Astrazeneca PLC
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Treatment Method
1.2.1 Global Unresectable Hepatocellular Carcinoma Treatment Market Size Growth Rate by Treatment Method, 2017 VS 2021 VS 2028
1.2.2 Novel T Cell Therapy
1.2.3 Chemotherapy
1.3 Market by Application
1.3.1 Global Unresectable Hepatocellular Carcinoma Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Unresectable Hepatocellular Carcinoma Treatment Market Perspective (2017-2028)
2.2 Unresectable Hepatocellular Carcinoma Treatment Growth Trends by Region
2.2.1 Unresectable Hepatocellular Carcinoma Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Unresectable Hepatocellular Carcinoma Treatment Historic Market Size by Region (2017-2022)
2.2.3 Unresectable Hepatocellular Carcinoma Treatment Forecasted Market Size by Region (2023-2028)
2.3 Unresectable Hepatocellular Carcinoma Treatment Market Dynamics
2.3.1 Unresectable Hepatocellular Carcinoma Treatment Industry Trends
2.3.2 Unresectable Hepatocellular Carcinoma Treatment Market Drivers
2.3.3 Unresectable Hepatocellular Carcinoma Treatment Market Challenges
2.3.4 Unresectable Hepatocellular Carcinoma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Unresectable Hepatocellular Carcinoma Treatment Players by Revenue
3.1.1 Global Top Unresectable Hepatocellular Carcinoma Treatment Players by Revenue (2017-2022)
3.1.2 Global Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Unresectable Hepatocellular Carcinoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Unresectable Hepatocellular Carcinoma Treatment Revenue
3.4 Global Unresectable Hepatocellular Carcinoma Treatment Market Concentration Ratio
3.4.1 Global Unresectable Hepatocellular Carcinoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Unresectable Hepatocellular Carcinoma Treatment Revenue in 2021
3.5 Unresectable Hepatocellular Carcinoma Treatment Key Players Head office and Area Served
3.6 Key Players Unresectable Hepatocellular Carcinoma Treatment Product Solution and Service
3.7 Date of Enter into Unresectable Hepatocellular Carcinoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Unresectable Hepatocellular Carcinoma Treatment Breakdown Data by Treatment Method
4.1 Global Unresectable Hepatocellular Carcinoma Treatment Historic Market Size by Treatment Method (2017-2022)
4.2 Global Unresectable Hepatocellular Carcinoma Treatment Forecasted Market Size by Treatment Method (2023-2028)
5 Unresectable Hepatocellular Carcinoma Treatment Breakdown Data by Application
5.1 Global Unresectable Hepatocellular Carcinoma Treatment Historic Market Size by Application (2017-2022)
5.2 Global Unresectable Hepatocellular Carcinoma Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Unresectable Hepatocellular Carcinoma Treatment Market Size (2017-2028)
6.2 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method
6.2.1 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022)
6.2.2 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028)
6.2.3 North America Unresectable Hepatocellular Carcinoma Treatment Market Share by Treatment Method (2017-2028)
6.3 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application
6.3.1 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022)
6.3.2 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028)
6.3.3 North America Unresectable Hepatocellular Carcinoma Treatment Market Share by Application (2017-2028)
6.4 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country
6.4.1 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022)
6.4.2 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size (2017-2028)
7.2 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method
7.2.1 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022)
7.2.2 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028)
7.2.3 Europe Unresectable Hepatocellular Carcinoma Treatment Market Share by Treatment Method (2017-2028)
7.3 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Application
7.3.1 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022)
7.3.2 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028)
7.3.3 Europe Unresectable Hepatocellular Carcinoma Treatment Market Share by Application (2017-2028)
7.4 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Country
7.4.1 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022)
7.4.2 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size (2017-2028)
8.2 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method
8.2.1 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022)
8.2.2 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028)
8.2.3 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Share by Treatment Method (2017-2028)
8.3 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Application
8.3.1 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Region
8.4.1 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size (2017-2028)
9.2 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method
9.2.1 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022)
9.2.2 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028)
9.2.3 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Share by Treatment Method (2017-2028)
9.3 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application
9.3.1 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Share by Application (2017-2028)
9.4 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country
9.4.1 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size (2017-2028)
10.2 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method
10.2.1 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022)
10.2.2 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028)
10.2.3 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Share by Treatment Method (2017-2028)
10.3 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Application
10.3.1 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Country
10.4.1 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Details
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Unresectable Hepatocellular Carcinoma Treatment Introduction
11.1.4 Pfizer Inc. Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.1.5 Pfizer Inc. Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Unresectable Hepatocellular Carcinoma Treatment Introduction
11.2.4 Eli Lilly Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.2.5 Eli Lilly Recent Developments
11.3 Bayer AG
11.3.1 Bayer AG Company Details
11.3.2 Bayer AG Business Overview
11.3.3 Bayer AG Unresectable Hepatocellular Carcinoma Treatment Introduction
11.3.4 Bayer AG Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.3.5 Bayer AG Recent Developments
11.4 Merck & Co. Inc.
11.4.1 Merck & Co. Inc. Company Details
11.4.2 Merck & Co. Inc. Business Overview
11.4.3 Merck & Co. Inc. Unresectable Hepatocellular Carcinoma Treatment Introduction
11.4.4 Merck & Co. Inc. Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.4.5 Merck & Co. Inc. Recent Developments
11.5 Bristol-Myers-Squibb Company
11.5.1 Bristol-Myers-Squibb Company Company Details
11.5.2 Bristol-Myers-Squibb Company Business Overview
11.5.3 Bristol-Myers-Squibb Company Unresectable Hepatocellular Carcinoma Treatment Introduction
11.5.4 Bristol-Myers-Squibb Company Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.5.5 Bristol-Myers-Squibb Company Recent Developments
11.6 Celgene Corporation
11.6.1 Celgene Corporation Company Details
11.6.2 Celgene Corporation Business Overview
11.6.3 Celgene Corporation Unresectable Hepatocellular Carcinoma Treatment Introduction
11.6.4 Celgene Corporation Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.6.5 Celgene Corporation Recent Developments
11.7 Eisai Co. Ltd
11.7.1 Eisai Co. Ltd Company Details
11.7.2 Eisai Co. Ltd Business Overview
11.7.3 Eisai Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Introduction
11.7.4 Eisai Co. Ltd Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.7.5 Eisai Co. Ltd Recent Developments
11.8 F. Hoffmann-La Roche Ltd
11.8.1 F. Hoffmann-La Roche Ltd Company Details
11.8.2 F. Hoffmann-La Roche Ltd Business Overview
11.8.3 F. Hoffmann-La Roche Ltd Unresectable Hepatocellular Carcinoma Treatment Introduction
11.8.4 F. Hoffmann-La Roche Ltd Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.8.5 F. Hoffmann-La Roche Ltd Recent Developments
11.9 Chugai Pharmaceutical Co. Ltd
11.9.1 Chugai Pharmaceutical Co. Ltd Company Details
11.9.2 Chugai Pharmaceutical Co. Ltd Business Overview
11.9.3 Chugai Pharmaceutical Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Introduction
11.9.4 Chugai Pharmaceutical Co. Ltd Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.9.5 Chugai Pharmaceutical Co. Ltd Recent Developments
11.10 Pharmaxis
11.10.1 Pharmaxis Company Details
11.10.2 Pharmaxis Business Overview
11.10.3 Pharmaxis Unresectable Hepatocellular Carcinoma Treatment Introduction
11.10.4 Pharmaxis Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.10.5 Pharmaxis Recent Developments
11.11 BeiGene
11.11.1 BeiGene Company Details
11.11.2 BeiGene Business Overview
11.11.3 BeiGene Unresectable Hepatocellular Carcinoma Treatment Introduction
11.11.4 BeiGene Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.11.5 BeiGene Recent Developments
11.12 Astrazeneca PLC
11.12.1 Astrazeneca PLC Company Details
11.12.2 Astrazeneca PLC Business Overview
11.12.3 Astrazeneca PLC Unresectable Hepatocellular Carcinoma Treatment Introduction
11.12.4 Astrazeneca PLC Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.12.5 Astrazeneca PLC Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer